精准医疗之基因检测(课件).pptVIP

  • 71
  • 0
  • 约1.58万字
  • 约 75页
  • 2018-12-23 发布于广东
  • 举报
KRAS突变与爱必妥无病情发展生存率和总生存率 Progression-free survival Overall survival of the 113 pooled patients according to the presence or absence of KRAS mutation (P=1.4*10-7 and P=0.0017, respectively). Astrid Lievre, et al. JOURNAL OF CLINICAL ONCOLOGY. 2008(26), 374 结直肠癌 BRAF突变与爱必妥无病情发展生存率和总生存率 Fig 1. (A) Progression-free survival and(B) overall survival in wild-type KRAS patients according to BRAF status. M, mutated; NM, nonmutated. Pierre Laurent-Puig,et al. J Clin Oncol,2009 结直肠癌 PIK3CA突变KRAS野生型结直肠癌对西妥昔单抗有更强的耐药性 PLOS ONE July 29, 2011 3.73 KRAS-BRAF-NRAS-PIK3CA检测 Lancet Oncol 2010; 11: 753–62 KRAS突变应

文档评论(0)

1亿VIP精品文档

相关文档